IDDI at the 4th Annual Next Gen Immuno-Oncology Virtual Congress

June 28, 2021

IDDI presenting and meeting at the 4th US Annual Next Gen Immuno-Oncology Virtual Congress 

The Congress addresses the challenges and future directions in Immuno-oncology research.

• On June 28, 13:15 – 13:45 (EST Time): Tomasz Burzykowski (PhD), Vice President, Research, IDDI will run a webinar on “EVALUATING TREATMENT EFFECT IN CLINICAL TRIALS IN IMMUNO-ONCOLOGY”
  In this session Prof. Burzykowski will discuss about the treatment effects on survival-type endpoints in randomized clinical trials (RCTs) in oncology that have been traditionally evaluated by using the proportional-hazard (PH) model. Also, observation on treatment effects incompatible with the PH assumption (like, for instance, delayed effects) in immuno-oncology (IO) will also be presented together with the statistical methods to best describe and test for treatment effects in RCTs in IO. A live Q&A session will be included for further discussion on the topic. 
  
  
• IDDI Experts will be available to discuss your challenges and see how we can help you achieve your goals faster!
  
  SCHEDULE A MEETING today by contacting Vicky Martin, IDDI’s Senior Director of Business Development US at vicky.martin@iddi.com or Robert Whitaker, IDDI Director, Business Development, West Coast USA at robert.whitaker@iddi.com
  
  

More information on the Congress’s Agenda and Registration can be found here.